Season 3 of Surfing The NASH Tsunami

S3-E51.1 - Preview of MAESTRO-NASH Results: a 2,000-Patient Phase 3 Trial

S3-E51.1 – Preview of MAESTRO-NASH Results: a 2,000-Patient Phase 3 Trial

The 2022 AASLD Liver Meeting takes place November 4th-8th in Washington DC in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. Key Opinion Leaders Stephen Harrison, Jörn Schattenberg and patient advocate Jeff McIntyre join Roger Green in a preview of presentations and posters of interest.

S3-E51 - A Preview of the 2022 AASLD Liver Meeting

S3-E51 – A Preview of the 2022 AASLD Liver Meeting

The 2022 AASLD Liver Meeting takes place November 4th-8th in Washington DC in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. Key Opinion Leaders Stephen Harrison, Jörn Schattenberg and patient advocate Jeff McIntyre join Roger Green in a preview of key presentations and posters of interest.

S3-E50.5 - FIB-4 as a Front-Line Tool for Primary Care Triage

S3-E50.5 – FIB-4 as a Front-Line Tool for Primary Care Triage

Roger Green and Louise Campbell are joined by patient advocates Michael Betel, Wayne Eskridge and Robert Mitchell-Thain to discuss patient involvement in putting a dent in Fatty Liver disease. This conversation explores the use of FIB-4 as a front-line tool for primary care. The advocates share their final thoughts on a change they can make in their country in the next 12 months that might extend beyond the country’s borders.

S3-E50.4 - Economics and Challenges of Pathway Design

S3-E50.4 – Economics and Challenges of Pathway Design

The panelists investigate the economics of pathway design within a wider discussion on the role of patient empowerment in putting a dent in Fatty Liver disease. This conversation observes challenges and opportunities for effective solutions.

S3-E50.3 - Patient Input for Clinical Care Pathways and Guidelines

S3-E50.3 – Patient Input for Clinical Care Pathways and Guidelines

Roger Green and Louise Campbell are joined by patient advocates Michael Betel, Wayne Eskridge and Robert Mitchell-Thain to discuss patient involvement in putting a dent in Fatty Liver. This conversation highlights patient advocate contributions toward developing clinical care pathways and guidelines.

S3-E50.2 - The Future of Digital Therapeutics and Patient Wellness Tools

S3-E50.2 – The Future of Digital Therapeutics and Patient Wellness Tools

Roger Green and Louise Campbell are joined by patient advocates Michael Betel, Wayne Eskridge and Robert Mitchell-Thain to discuss patient involvement in putting a dent in Fatty Liver. This conversation explores the prospect of digital therapeutics as a Pharma-supported patient wellness tool.

S3-E50.1 - Patient Needs and Inputs for Trial Design

S3-E50.1 – Patient Needs and Inputs for Trial Design

Roger Green and Louise Campbell are joined by patient advocates Michael Betel, Wayne Eskridge and Robert Mitchell-Thain to discuss patient involvement in putting a dent in Fatty Liver. This conversation explores patient needs and inputs for trial design and the extent to which they are considered.

S3-E50 – Focus on Patient Advocacy

Roger Green and Louise Campbell are joined by patient advocates Michael Betel, Wayne Eskridge and Robert Mitchell-Thain to discuss patient involvement in putting a dent in Fatty Liver. The group explores topics ranging from the economics of drug development to the future of digital therapeutics, all centering around the patient perspective.

S3-E49.4 - Delivering Meaningful Liver Test Results to Patients

S3-E49.4 – Delivering Meaningful Liver Test Results to Patients

Roger Green and Louise Campbell are joined by Dr Kathryn Jack, Professors Ian Rowe and William Alazawi to discuss the recent NICE meeting on use of VCTE in primary care settings. In this conversation, the group explores how to create and train on delivering meaningful test results to patients.

S3-E49.3 - Linking Liver Outcomes and Socioeconomic Status

S3-E49.3 – Linking Liver Outcomes and Socioeconomic Status

Roger Green and Louise Campbell are joined by Dr Kathryn Jack, Professors Ian Rowe and William Alazawi to investigate the link between socioeconomic status and liver health outcomes. In this episode, the group discusses the challenges of developing accessible pathways and who will administer FibroScan in a community setting.

S3-E49.1 - NICE on FibroScan for Primary Care

S3-E49.1 – NICE on FibroScan for Primary Care

Roger Green and Louise Campbell are joined by Professor Ian Rowe and Dr Kathryn Jack to discuss the recent NICE meeting on use of VCTE in primary care settings. The group explores the dynamic challenges of utilizing FibroScan and other noninvasive tests (NITs) for best practice in community settings.

S3-E49 NICE and VCTE Use in Community Settings

S3-E49 NICE and VCTE Use in Community Settings

Roger Green and Louise Campbell are joined by Professors Ian Rowe and William Alazawi and Dr Kathryn Jack to discuss the recent NICE meeting on use of FibroScan in primary care settings. As part of the discussion, the group explores the dynamic challenges of utilizing FibroScan and other noninvasive tests (NITs) for best practice.

S3-E48.5 - Phase 3 Results of the REVERSE Trial by Intercept

S3-E48.5 – Phase 3 Results of the REVERSE Trial by Intercept

Stephen Harrison and Mazen Noureddin join Jörn Schattenberg, Louise Campbell and Roger Green to review some of the most exciting and promising data of the last decade in NASH drug development. In this conversation the group discusses Phase 3 results of the REVERSE trial by Intercept.

S3-E48.3 - More Positive Phase 2B Results from Poxel

S3-E48.3 – More Positive Phase 2B Results from Poxel

Stephen Harrison and Mazen Noureddin join Jörn Schattenberg, Louise Campbell and Roger Green to review some of the most exciting and promising data of the last decade in NASH drug development. In this conversation, the group explores more positive Phase 2B results from Poxel’s DESTINY-1 Trial.

S3-E48.2 - Phase 2B 'Wow!' Results from Akero’s HARMONY Trial

S3-E48.2 – Phase 2B ‘Wow!’ Results from Akero’s HARMONY Trial

Stephen Harrison and Mazen Noureddin join Jörn Schattenberg, Louise Campbell and Roger Green to review some of the most exciting and promising data of the last decade in NASH drug development. In this conversation, the panelists discuss eye-opening Phase 2B results from Akero’s HARMONY Trial.

S3-E48.1 - Results of Altimmune’s 12 week Phase 1B Study of Pemvidutide

S3-E48.1 – Results of Altimmune’s 12 week Phase 1B Study of Pemvidutide

Stephen Harrison and Mazen Noureddin join Jörn Schattenberg, Louise Campbell and Roger Green to review some of the most exciting and promising data of the last decade in NASH drug development. In this conversation, the panelists discuss the positive results of Altimmune’s 12 week Phase 1B study of pemvidutide.

Review of Exciting Clinical Trial Press Releases

S3-E48 – Review of Exciting Clinical Trial Press Releases

Stephen Harrison and Mazen Noureddin join regulars Jörn Schattenberg, Louise Campbell and Roger Green to review five recent press releases reporting on trial results from Altimmune, Akero, Poxel, Axcella and Intercept. Dubbed a Wow! episode, the panelists explore some of the most exciting and promising data of the last decade in NASH drug development.

S3-E47.1 - Collaborative energies shifting the force around Fatty Liver

S3-E47.1 – Collaborative energies shifting the force around Fatty Liver

Surfers Jörn Schattenberg, Louise Campbell and Roger Green discuss what they anticipate will be the major stories in NAFLD and NASH over the next 6-12 months. In this conversation, they explore the increasing demand for collaboration between medical specialties as opinion leaders come to see NAFLD as part of a constellation of metabolic diseases.

S3-E47 - What does the next year hold for the NAFLD metabolic disease link?

S3-E47 – What does the next year hold for the NAFLD metabolic disease link?

Surfers Roger Green, Jörn Schattenberg and Louise Campbell embark on their first exclusive discussion together in a while without any guest panelists. After several weeks of attending and reviewing conferences, the trio take the opportunity to talk about what the next year holds for the NAFLD-metabolic disease link.

S3-E46.6 - From the Vault: Can Weight Loss From GLP-1s or Double/Triple Agonists Emulate the Effects of Bariatric Surgery in SPLENDOR?

S3-E46.6 – From the Vault: Can Weight Loss From GLP-1s or Double/Triple Agonists Emulate the Effects of Bariatric Surgery in SPLENDOR?

In a review of the 2022 NAFLD Summit, program speakers Mazen Noureddin, Sven Francque and Hannes Hagström join Roger Green to discuss the impact of weight change and lifestyle modification in clinical trials while utilizing insights from the bariatric and diabetes fields. This episode From the Vault comes from Season 2, Episode 61.3 where Roger Green, Stephen Harrison, Ali Aminian and Wayne Eskridge discuss how weight loss and GLP-1s or Double/Triple Agonists in relation to SPLENDOR.

S3-E46.5 - Discussing NITs and Final Thoughts on NAFLD Summit

S3-E46.5 – Discussing NITs and Final Thoughts on NAFLD Summit

Program speakers Mazen Noureddin, Sven Francque and Hannes Hagström join Roger Green, on-site from Dublin to review their thoughts and key takeaways immediately after the NAFLD Summit ended. In this final conversation, the group discusses NITs and what will change between now and when this conference convenes next year.

S3-E46.4 - Weight Change and Lifestyle Modification in Clinical Trials

S3-E46.4 – Weight Change and Lifestyle Modification in Clinical Trials

Program speakers Mazen Noureddin, Sven Francque and Hannes Hagström join Roger Green, on-site from Dublin to review their thoughts and key takeaways immediately after the NAFLD Summit ended. In this conversation, the group discusses the impact of weight change and lifestyle modification in clinical trials.

S3 E46.3 - Discussing Clinical Trial Design at the NAFLD Summit

S3 E46.3 – Discussing Clinical Trial Design at the NAFLD Summit

Program speakers Mazen Noureddin, Sven Francque and Hannes Hagström join Surfer, Roger Green, on-site from Dublin to review their thoughts and key takeaways immediately after the NAFLD Summit ended. In this conversation, the group explores issues around clinical trial design, focusing specifically on the value of Phases 2a and 2b and whether improvement in patient self-management during trials is a research artifact or a replication of reality.

S3-E46.2 - NAFLD Summit in Context and Learning from Failed Trials

S3-E46.2 – NAFLD Summit in Context and Learning from Failed Trials

Program speakers Mazen Noureddin, Sven Francque and Hannes Hagström join Surfer, Roger Green, on site from Dublin to review their thoughts and key takeaways immediately after the NAFLD Summit ended. In this conversation, the group contextualizes and compares the NAFLD Summit to other major liver conferences and meetings. The group also assesses Session 9 from Friday, a series of case studies on why trials fail.

S3-E46.1 - Underreported Alcohol Use and Treating Comorbidities

S3-E46.1 – Underreported Alcohol Use and Treating Comorbidities

Program speakers Mazen Noureddin, Sven Francque and Hannes Hagström join Surfer, Roger Green, on site from Dublin to review their thoughts and key takeaways immediately after the NAFLD Summit ended. In this conversation, the group discusses underreported alcohol use in clinical trials and the impact of treating comorbidities on the treatment of NAFLD.

S3-E46 - A Review of the 2022 NAFLD Summit from Dublin

S3-E46 – A Review of the 2022 NAFLD Summit from Dublin

The 2022 NAFLD Summit proved to be an in-depth, successful conference brought to life by key opinion leaders in fatty liver and metabolic disease from around the world. In Season 3, Episode 46, Surfer Roger Green hosts a review on site in Dublin with presenting speakers Mazen Noureddin, Sven Francque and Hannes Hagström.

S3-E45.4 - Paris Review: NITs, Metabolic Disease and Final Thoughts

S3-E45.4 – Paris Review: NITs, Metabolic Disease and Final Thoughts

In a review of Paris NASH 2022, Surfers Roger Green, Louise Campbell, and Jörn Schattenberg are joined by patient advocate, Jeff McIntyre. In this final conversation, the group explores the rest of the Day Two program, focusing on the development of an NIT diagnostic pathway. Finally, each offers their closing remarks on being a part of the 8th Paris NASH Meeting and what the future looks like in this space.

S3-E45.3 - Paris Review: Session 5 on Clinical Trial Innovation

S3-E45.3 – Paris Review: Session 5 on Clinical Trial Innovation

In a review of Paris NASH 2022, Surfers Roger Green, Louise Campbell, and Jörn Schattenberg are joined by patient advocate, Jeff McIntyre. In this conversation, the group discusses presentations on adaptive trial strategies, trial recruitment and reducing screen fail rates, and the impact of educating patients on better self-care.

S3-E45.2 - Paris Review: Opening and closing sessions

S3-E45.2 – Paris Review: Opening and closing sessions

In a review of Paris NASH 2022, Surfers Roger Green, Louise Campbell, and Jörn Schattenberg are joined by patient advocate, Jeff McIntyre. In this conversation, the group discusses the opening and closing sessions, data collection and the rate of growth for cirrhosis, and Fatty Liver in the metabolic context.

S3-E45 - A Review of Paris NASH Meeting 2022 with Jeff McIntyre

S3-E45 – A Review of Paris NASH Meeting 2022 with Jeff McIntyre

The importance of integrating the NAFLD and NASH field within a wider scope of metabolic health was emphasized at the 8th Paris NASH Meeting. Last week, Surfers Roger Green, Louise Campbell and Jörn Schattenberg were in attendance alongside patient advocate and episode guest, Jeff McIntyre.

S3-E44.5 - 1 on 1 with Jeff Lazarus: Focus on NAFLD Summit

S3-E44.5 – 1 on 1 with Jeff Lazarus: Focus on NAFLD Summit

In Part 2 of Season 3, Episode 44, host Roger Green kicks off a series of 1 on 1 interviews with friend of the podcast, Dr. Jeffrey Lazarus. In this conversation, the two discuss a preview of NAFLD Summit 2022 in Dublin, 15-17 September.

S3-E44.3 - Anticipated Aftermath: Outcomes of Paris NASH

S3-E44.3 – Anticipated Aftermath: Outcomes of Paris NASH

In this conversation, Surfers Roger Green, Louise Campbell, and Jörn Schattenberg are joined by Rachel Zayas to talk about Paris NASH 2022. The group explores their hopes in terms of immediate and long term outcomes of the meeting.

S3-E44.2 - NASH and an Integrated Multi-Specialty Approach

S3-E44.2 – NASH and an Integrated Multi-Specialty Approach

In a preview of the 2022 Paris NASH Meeting, Surfers Roger Green, Louise Campbell, and Jörn Schattenberg are joined by Rachel Zayas to discuss the opening session. The group explores potential insights that will contextualize NASH in the scope of an integrated multi-specialty approach.

S3-E44.1 - Paris NASH Meeting Preview: Program Highlights

S3-E44.1 – Paris NASH Meeting Preview: Program Highlights

In a preview of the 2022 Paris NASH Meeting, Surfers Roger Green, Louise Campbell, and Jörn Schattenberg are joined by Rachel Zayas to discuss what each looks forward to most in the upcoming panels and discussions. “Brave one go first.”

S3-E44 - A Preview of Paris NASH and NAFLD Summit 2022

S3-E44 – A Preview of Paris NASH and NAFLD Summit 2022

In a preview of Paris NASH and the NAFLD Summit 2022, Surfers Roger Green, Louise Campbell, and Jörn Schattenberg are joined by Rachel Zayas to discuss what each looks forward to in the upcoming meeting. Additionally in a part 2 of this episode, Prof. Jeff Lazarus from the Barcelona Institute for Global Health joins Roger for a one on one interview. Jeff shares a snapshot into what he has been working on over the past few months, as well as his anticipated interests on the NAFLD Summit agenda.

S3-E43.5 - The Future of Combination Agents in NASH Therapy

S3-E43.5 – The Future of Combination Agents in NASH Therapy

First author Naim Alkhouri and last author Mazen Noureddin join the Surfers to discuss their recently published article, Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial (JHEP, 2022). This episode explores the future of combination agents in NASH Therapy.

S3-E43.4 - Optimizing Combination Agents

S3-E43.4 – Optimizing Combination Agents

First author Naim Alkhouri and last author Mazen Noureddin join the Surfers to discuss their recently published article, Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial (JHEP, 2022). This episode explores the optimization of combination agents in NASH Therapy. The conversation takes a broader look into the strategies behind developing and pairing combination agents and the role they can potentially play in a wider scope of treatment.

S3-E43.3 - Science Partnerships and NASH Trials

S3-E43.3 – Science Partnerships and NASH Trials

First author Naim Alkhouri and last author Mazen Noureddin join the Surfers to discuss their recently published article, Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial (JHEP, 2022). In this conversation, the panel continues its discussion around strategies for deciding which agents to combine in trials, along with a plea for larger BioPharma companies to pursue science partnerships with smaller companies even if there are no strong commercial bonds between the companies. In the end, discussion of the ongoing LEGEND trial gives panelists a chance to express different opinions about combination agent strategy.

S3-E43.2 - Finding the Right Combinations in NASH Therapy

S3-E43.2 – Finding the Right Combinations in NASH Therapy

n Season 3 Episode 43, first author Naim Alkhouri and last author Mazen Noureddin join the Surfers to discuss their recently published article, Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial (JHEP, 2022). In this conversation, the group explores the role of NITs as the prime diagnostic tool alongside combination agents, and discusses practical issues surrounding patient management and theoretical ones in deciding which agents to combine for trials.

S3-E43.1 - Combination Agents for Fibrotic Regression

S3-E43.1 – Combination Agents for Fibrotic Regression

In Season 3 Episode 43, first author Naim Alkhouri and last author Mazen Noureddin join the Surfers to discuss their recently published article, Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial (JHEP, 2022). The theme of the episode is to explore the role of combination agents for NASH therapy over time. This opening conversation focuses on the design and execution of the triple-agent study, and how it may contribute to fibrotic regression.

S3-E43 - Combination Agents: A Cornerstone Of Future NASH Therapy?

S3-E43 – Combination Agents: A Cornerstone Of Future NASH Therapy?

Naim Alkhouri and Mazen Noureddin join the Surfers to discuss the future role of Combination Agents with NASH therapy, stemming from their recently published article, Safety and efficacy of combination therapy with semaglutide,cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial (JHEP, 2022). The conversation focuses more broadly on the benefits and future of combination therapies for NASH patients.

S3-E42.4 - Allied Health and Patient Empowerment for NAFLD

S3-E42.4 – Allied Health and Patient Empowerment for NAFLD

Louise Campbell hosts this week’s NASH Tsunami and talks about educating on liver outcomes. Jörn Schattenberg, Robert Mitchell-Thain, Michelle Clayton and Stephen Callaghan provide their thoughts on education and social resources within the framework of developing a NAFLD pathway.

S3-E42.3 - Allied Health and Patient Empowerment for NAFLD

S3-E42.3 – Allied Health and Patient Empowerment for NAFLD

Louise Campbell hosts this week’s NASH Tsunami to talk about patient empowerment with Jörn Schattenberg, Robert Mitchell-Thain, Michelle Clayton and Stephen Callaghan. The group explores measuring pathways and changing healthcare dynamics through digitization and technology.

S3-E42.2 - Allied Health and Patient Empowerment for NAFLD

S3-E42.2 – Allied Health and Patient Empowerment for NAFLD

Louise Campbell hosts this week’s NASH Tsunami while host, Roger Green, finds a new surf vacationing on the Jersey Shore. In this segment, the role of allied health professionals and patient empowerment is discussed in the context of developing a Sustainable Development Goal Framework for NAFLD.

S3-E42.1 - Allied Health and Patient Empowerment for NAFLD

S3-E42.1 – Allied Health and Patient Empowerment for NAFLD

Louise Campbell hosts this week’s NASH Tsunami and talks about the role of allied health professionals and patient empowerment in developing a NAFLD pathway. In this conversation, Jörn Schattenberg discusses a paper he co-authored that aims to guide multisectoral action on NAFLD through a societal approach.

S3-E42 - Allied Health and Patient Empowerment for NAFLD

S3-E42 – Allied Health and Patient Empowerment for NAFLD

Louise Campbell hosts this week’s NASH Tsunami while host, Roger Green, finds a new surf vacationing on the Jersey Shore. In this episode, the role of allied health professionals and patient empowerment is discussed in the context of a Sustainable Development Goal Framework for NAFLD.

S3-E41.5 - Improving NASH Clinical Trials By Reducing Screen Fail Rates

S3-E41.5 – Improving NASH Clinical Trials By Reducing Screen Fail Rates

The “Band” (Jörn Schattenberg, Stephen Harrison, Louise Campbell and Roger Green) gets back together with no other guests to talk NASH Clinical Trials, improving screen fail rates, finding more patients and, generally, what has changed since Jörn co-authored his 2020 article on the NASH Clinical Trial Graveyard.

S3-E41.4 - Improving NASH Clinical Trials By Reducing Screen Fail Rates

S3-E41.4 – Improving NASH Clinical Trials By Reducing Screen Fail Rates

The “Band” (Jörn Schattenberg, Stephen Harrison, Louise Campbell and Roger Green) gets back together with no other guests to talk NASH Clinical Trials, improving screen fail rates, finding more patients and, generally, what has changed since Jörn co-authored his 2020 article on the NASH Clinical Trial Graveyard.

Subscribe for free. New podcasts Wednesday Evening / Thursday Morning.

Apple
Spotify
Google
Stitcher
Buzzsprout
YouTube
SoundCloud